Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
6.77
0.19 (2.89%)
At close: Jun 05, 2025, 3:59 PM
6.98
3.12%
After-hours: Jun 05, 2025, 07:47 PM EDT
2.89% (1D)
Bid | 6.72 |
Market Cap | 688.81M |
Revenue (ttm) | n/a |
Net Income (ttm) | -47.35M |
EPS (ttm) | -0.45 |
PE Ratio (ttm) | -15.04 |
Forward PE | -11.76 |
Analyst | Buy |
Ask | 6.98 |
Volume | 2,354,999 |
Avg. Volume (20D) | 2,630,639 |
Open | 6.46 |
Previous Close | 6.58 |
Day's Range | 6.35 - 6.90 |
52-Week Range | 2.30 - 7.48 |
Beta | 0.53 |
About TRVI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TRVI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TRVI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
-5.85%
Trevi Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
4 days ago
-2.92%
TRVI stock has given up its prior gain. Trevi Therapeutics shares were trading higher after the company announced positive topline results from its Phase 2b CORAL trial of Haduvio.

2 months ago · seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call TranscriptTrevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini -...